Ceftazidime dosing in obese patients: is it time for more?

Author:

Fanton D’Andon Cornélie1,Correia Patricia2,Rigaill Josselin3,Kably Benjamin4,Perinel-Ragey Sophie2,Launay Manon1ORCID

Affiliation:

1. – Gaz du Sang, Hôpital NordLaboratoire de Pharmacologie – Toxicologie , CHU de Saint-Etienne, France

2. Service de Médecine Intensive et Réanimation G, CHU de Saint-Etienne, Saint Etienne, France

3. Department of Infectious Agents and Hygiene, University-Hospital of Saint-Etienne, Saint-Etienne, France

4. Laboratoire de Pharmacologie, Hôpital Européen Georges Pompidou, Paris, France

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Reference96 articles.

1. WHO. Obesity and overweight [Internet]. 2021 [cited 2021 Oct 2]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

2. Beyond BMI - Phenotyping the Obesities

3. Obesity as a medical problem

4. Obesity as a Major Risk Factor for Cancer

5. Representation of obese participants in obesity-related cancer randomized trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3